We harness the power of epigeneticsWhat we do
Cambridge Epigenetix is pioneering new sequencing and diagnostic tools to revolutionise cancer diagnosis and therapeutics, using the power of the 5-hydroxymethylcytosine (5hmC) epigenetic modification and the other epigenetic variants of 5-methylcytosine, alongside genetics..Contact us
Epigenetics is vitalWhy we do it
Our proprietary discovery platform enables the identification of disease-specific hydroxymethylated (5hmC) DNA from blood and tissue samples — enhancing human health through more accurate and earlier diagnosis, improved patient stratification and the development of liquid biopsy-based tests.
Our approach & capabilities
Partner and Pioneer
We focus on the 5hmC epigenetic modification and have a patent protected platform for detection of highly accurate signatures for a variety of diseases using this mark.
Developing proprietary technology to enhance epigenetics research.
Delivering the next generation of diagnostic assays.
Identifying novel therapeutic targets in collaboration with Pharma.
Disruptive technologies to improve human healthOur technologiesLearn more
Investing in the future
Cambridge Epigenetix's pioneering work and unrivaled capabilities in harnessing epigenetic insights will unleash the potential of precision medicine.Our Investors